-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) Ticks Higher on Takeover Speculation
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Lowered to $50 at Clear Street
-
-
-
-
-
-
-
CRISPR presents preclinical data for gene therapy targeting rare disorder
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) Misses Q2 EPS by 100c
-
-
-
-
-
-
-
Chardan: 'We think CRSP's emergence as a credible player in the space could thus drive further valuation upside'
-
-
-
-
-
-
-
Verve Therapeutics takeover has 'positive readthrough' for gene editing space - BMO Capital
-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on CRISPR Therapeutics (CRSP)
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

